SAN FRANCISCO, June
12, 2014 – Invitae Corporation, a genetic
information company, today announced that it now offers multi-gene testing for
hereditary pancreatic cancer, providing clinicians with a reliable, fast and
affordable option for their cancer patients and their families. With results typically
available within three weeks, this panel includes an analysis of 17 genes and
currently is the most comprehensive panel available. The test is available
globally and at a contracted price of $1,500 in the United States.
The new Invitae
Hereditary Pancreatic Cancer Panel covers the genetic associations most
commonly linked to an increased risk of pancreatic cancer and includes the
following genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PALLD, PMS2, STK11, TP53 and VHL. In addition,
Invitae offers hereditary pancreatitis genes CFTR and SPINK1, which some
providers choose when assessing a patient for hereditary pancreatic cancer.
These genes can be included in an Invitae requisition at no additional charge.
Additional
hereditary cancer panels are available, including testing for BRCA1 and BRCA2,
Lynch Syndrome and other colon cancers, and a 29-gene hereditary cancer
syndromes panel.
In addition to
covering more genes than tests available from other providers, Invitae’s newest
cancer panel provides clinicians and patients with answers more rapidly, at a
lower cost.
“Genetic
testing for inherited pancreatic cancer is particularly important as most
patients are diagnosed at an advanced stage,” said Tuya Pal, MD, Clinical
Geneticist, Moffitt Cancer Center. “Given that there are multiple genes that
may predispose to inherited pancreatic cancer, multi-gene tests may help us to
refine medical management and treatment decisions in affected patients and
identify at-risk family members who may benefit from targeted cancer screening
and prevention options.”
According to the American Cancer Society, approximately 46,420 people in the United
States will be diagnosed with pancreatic cancer, and an estimated 39,590 people
will die of pancreatic cancer in 2014.
“Invitae’s new
pancreatic cancer panel delivers greater genetic information and thus provides
healthcare providers with an important tool to help address the clinical
challenges of detecting hereditary pancreatic cancer and managing treatment
decisions,” said Invitae’s Federico Monzon, MD. “The release of this new panel
enables us to help address a new group of patients who may be at risk for
pancreatic cancer with a test that is not only reliable, but affordable and
provides rapid results.”
About Invitae
Corporation
Invitae is a genetic information company whose mission is to bring
genetic information into routine medical practice to improve the quality of
healthcare for billions of people.
Specializing in genetic diagnostics for hereditary disorders, Invitae is
aggregating the world’s genetic tests into a single service with better
quality, faster turnaround time and a lower price than most single-gene
diagnostic tests today. Invitae has raised $87 million from investors,
including Thomas McNerney Partners, Casdin Capital, Genesys Capital, Genomic Health,
Inc.
(NASDAQ: GHDX) and Redmile
Group.
For further information,
please visit www.invitae.com.
Contact:
Katherine
Stueland
844-233-4492
pr@invitae.com